Seagen announces results from pivotal mountaineer trial demonstrating clinically meaningful antitumor activity of tukysa® (tucatinib) in combination with trastuzumab in previously treated her2-positive metastatic colorectal cancer

Bothell, wash.--(business wire)--seagen inc. (nasdaq:sgen) today announced full results from the pivotal phase 2 mountaineer trial, which showed tukysa® (tucatinib) in combination with trastuzumab was well-tolerated with durable responses in patients with previously treated her2-positive metastatic colorectal cancer (mcrc). these late-breaking data were presented in an oral session at the european society for medical oncology (esmo) world congress on gastrointestinal cancer on july 2 in barcelo
SGEN Ratings Summary
SGEN Quant Ranking